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Background: Eight percent of people in the UK are estimated to have persistent (chronic) neuropathic pain, and
for many there is no effective treatment. Medications are the most common first-line treatment but often have
limited benefit or adverse events. Surgical treatments, such as spinal cord stimulation, are then often considered.
External non-invasive peripheral nerve stimulation (EN-PENS) is a form of electrical stimulation that involves placing
a pen-shaped electrode onto the skin, which can be easily self-administered by patients. Observational studies
suggest that EN-PENS may relieve pain for people with localised neuropathic pain; however, there is currently no
evidence from controlled trials to confirm the efficacy and confidently determine the effect size for patients with
longstanding neuropathic pain.
Methods: EN-PENS is a single-site, blinded, randomised controlled parallel-group superiority add-on trial with a
1:1 allocation ratio, designed to evaluate the efficacy of treatment versus control treatment in 76 patients with
longstanding neuropathic pain following peripheral nerve injury. Patients with moderate to -severe neuropathic
pain following peripheral nerve injury will be randomised to receive either the active or control treatment, followed
by an optional treatment extension or treatment switch to the alternative treatment arm. The primary outcome is
average 24-h pain intensity recorded on an 11-point (0–10) numerical rating scale, averaged over the last 7 days of
treatment.
Discussion: Study results will be used to inform potential treatment efficacy and cost-effectiveness of EN-PENS for
this population group.
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Neuropathic pain can arise peripherally or centrally as a
direct consequence of a lesion or disease affecting the
somatosensory system [1]. Pain can persist long after the
initial cause has resolved. An estimated 8 in every 100
people in the UK have persistent chronic neuropathic
pain [2, 3]. Neuropathic pain is often severely debilitating,
it impinges on the physical, economic and emotional well-
being of patients and is associated with low quality of life
(QOL) [4].
Neuropathic pain is very challenging to manage be-
cause of the heterogeneity of its aetiology and underlying
mechanisms [5].
Current management guidelines are heavily weighted
on pharmacotherapy, often with modest outcomes [6, 7].
When pharmacotherapy management is measured as
sub-optimal, either due to adverse events or insufficient
pain relief, next-line therapy options include surgical
lesioning or neuromodulation therapy [8]. A disadvan-
tage of surgical lesioning is that it is non-adjustable and
not reversible. Many procedures such as neurotomies have
been discontinued in clinical practice. Neuromodulation
therapy involves using electrical or chemical technology
that acts directly upon nerves to alter or modulate nerve
activity. The majority of neuromodulation technologies
are invasive. Treatments such as spinal cord stimulation
(SCS), dorsal root ganglion (DRG) stimulation and deep
brain stimulation (DBS) require surgical implants. Less in-
vasive technologies such as percutaneous electrical nerve
stimulation (PENS) involve electrical stimulation of nee-
dles inserted within the skin to target peripheral nerves
[9]. A disadvantage of such therapies is that the patient
will require invasive procedures to obtain benefits [10, 11].
Non-invasive neuromodulation technologies include
external non-invasive peripheral nerve stimulation (EN-
PENS) and transcutaneous electrical nerve stimulation
(TENS). EN-PENS is a neuromodulation technology in
which an electrode is positioned on the skin over the
injured nerve, and low-frequency electrical stimulation
(1–2 Hz) is applied to the nerve. This stimulation mode
aims to achieve long-lasting analgaesia through a specific
mechanism, preferential activation of superficial noci-
ceptive A-delta fibres inducing long-term depression
(LTD) of synaptic strength [12–15]. These effects can
last up to a few days [16], rendering this an attractive
stimulation mode for intermittent applications. Patients
can also easily be taught to self-administer treatment
safely at home.
In contrast to EN-PENS, TENS, another non-invasive
form of neuromodulation, typically activates A-beta
fibres not involved in LTD when used in conventional
mode (50–100 Hz typically) [17]. Although when used at
very low frequency it may theoretically elicit LTD, it
then requires much higher current to overcome the lowcurrent density under the electrode [12, 13, 15, 18]. Pub-
lished evidence regarding the effects of LTD is largely
supported by animal and laboratory-based studies, but
as yet clinical human study evidence is lacking.
The first prospective cohort study on the use of EN-
PENS in neuropathic pain demonstrated significant pain
reduction in persons with chronic neuropathic pain post
peripheral nerve injury (PPNI) or complex regional pain
syndrome (CRPS) (n = 20, prospectively assessed, 2.8
numerical rating scale (NRS) points average reduction,
CI 1.6–4.0, p < 0.001). No treatment-related adverse
events were reported. Significant improvements in QOL
(measured using the EuroQol (EQ)-5D-5 L) and function
(using the Brief Pain Inventory Interference Subscale
and the task-specific scale) were also reported [19]. This
study identified a trend toward patients with PPNI dem-
onstrating greater reductions in pain for longer periods
than patients with CRPS.
Further review of long-term EN-PENS efficacy (n = 5,
average follow-up 3.5 years) indicated treatment benefits
beyond those immediately following treatment [20]. The
analgaesic effect remained stable for at least 1 year,
with one to two treatments/day, with no evidence of
tolerance.
This initial study provides proof of concept for the
efficacy of EN-PENS in reducing pain in persons with
PPNI and CRPS who have moderate to severe pain
intensity, with no adverse events reported. These data
suggest that this treatment may improve function and
QOL. Therefore, the potential of EN-PENS as a safe, ef-
fective and cost-effective treatment option for those with
chronic neuropathic pain, for whom effective treatment
options may be limited, warrants further consideration.
Aside from the initial study described, current evidence
for this modality exists only in the form of conference
abstracts describing case series [21–25]. Results report
positive responses in terms of immediate pain relief
following treatment primarily in patients with neuropathic
pain.
It is important to consider this potentially effective
treatment in a randomised controlled trial (RCT) with a
larger group of patients. Previous study results do not
allow for the exclusion of possible moderate long-lasting
changes in the pain intensity after stopping EN-PENS
treatment [19]; therefore, a crossover RCT design is not
feasible.
The primary objective of this trial is to establish clinical
efficacy and a more confident estimate of the effect size of
EN-PENS treatment to reduce pain in patients with
moderate to severe neuropathic pain associated with
definite or probable peripheral nerve injury.
Secondary objectives are to evaluate the impact of this
treatment in terms of QOL and day-to-day function.
Further objectives are to gain a better understanding of
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to perform abilities in the presence of pain), reduction of
allodynia, potential mode of action, cost-effectiveness and
health care resource use (e.g. whether treatment can neg-
ate the need for more complex surgical treatments and/or
reduce the need for drug treatment).
Methods
Trial design
The EN-PENS trial is a single-site, blinded, randomised
controlled parallel-group superiority add-on trial with a
1:1 allocation ratio.
Following screening, 76 patients will be randomised to
receive either active or control (sham) treatment (38 in
each treatment arm). Participants and the research
nurses providing the training and undertaking the study
assessments will be blinded. Participants will receive
training and supportive materials on use of the neuro-
modulation stimulator (active or control). Once compe-
tent at using the EN-PENS machine, participants will
enter the 3-month home loan treatment phase. At the
end of the treatment phase, a 3-month optional choice
of treatment extension or swap to the other treatmentFig. 1 EN-PENS Study flow chartarm will be offered (see the flow diagram of Fig. 1). The
study duration will be 36 months (from study setup to
analysis).
Setting
This will be a single-site study conducted at a neurosci-
ences research centre in a tertiary specialist neurosciences
hospital providing a pain management service.
Recruitment and screening
Patients will be identified through pain clinics at the
study site for the trial. Nearby secondary care pain
clinics and orthopaedic departments have been made
aware of the study and, as with current practice, will be
able to refer patients to the centre for specialised
treatment not currently offered within secondary care.
Potentially eligible patients will be given an information
leaflet regarding the study. Patients will contact or be
contacted 1 week after receiving the leaflet to ascertain
if they have any questions and arrange a screening ap-
pointment. Screening in respect to inclusion and exclu-
sion criteria will be conducted by the study Principal
Investigator (PI). Confirmation of eligibility with respect
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following screening.
Screen failures may be rescreened only where there
is a short-term reason for ineligibility, such as an
ongoing acute illness. A screening log will be kept on
site to document details of patients invited to be
screened for participation in the study. For patients
who decline or are ineligible, this will document any
reasons available for non-participation (where pro-
vided). The log will ensure potential participants are
only approached once. The original signed consent
form will be retained in the investigator site file, with
a copy in the participant’s hospital medical notes and
a copy provided to the participant. The participant
will specifically consent to their general practitioner
(GP) being informed of their participation in the
study. The right to refuse to participate without
giving reasons will be respected.
Inclusion criteria
The inclusion criteria are:
 Chronic neuropathic pain following peripheral nerve
injury, definite or probable (the grading of certainty
for the presence of neuropathic pain includes
definite neuropathic pain: all (1–4); probable
neuropathic pain: 1 and 2, plus either 3 or 4 [1]:1. Pain with a distinct neuroanatomically plausible
distribution
2. A history suggestive of a relevant lesion or
disease affecting the peripheral or central
somatosensory system
3. Demonstration of the distinct neuroanatomically
plausible distribution by at least one confirmatory
test
4. Demonstration of the relevant lesion or disease
by at least one confirmatory test. ≥ 12 months duration of pain. Post-traumatic nerve
regeneration is usually complete at 12 months, so that
inclusion of this group will reduce the likelihood of
pain relief due to nerve regeneration [26].
 Adults aged 18 or older.
 Moderate to severe pain intensity: average 24-h pain
intensity over 7 days at baseline of ≥ 5/10 but not
dropping below 4 on any single day on an 11-point
(0–10) NRS.
 Pain localised to the distribution of one to two
peripheral nerves (to limit the time burden with
respect to treatment application).
 Distribution of pain that will allow for the nerve to
be stimulated proximally from the areas of pain.
Invasive peripheral nerve stimulation (PNS) trialevidence suggests analgaesia is maximised when
stimulation is used in this way [27].
 Medications that numb affected areas should be
discontinued prior to the study: lidocaine patches
2 weeks prior, capsaicin treatments (at both low and
high concentrations) 4 months prior to EN-PENS to
allow nerve endings to grow back.
 Patients should have trialled first-line pharmacotherapy.
First-line treatments include tricyclic antidepressants,-
serotonin-noradrenaline reuptake inhibitors, pregabalin
or gabapentin [6].
 Moderate to severe brush stroke allodynia, defined
as pain of ≥5/10 on an 11-point (0–10) NRS when a
brush stroke is applied to the affected area (average
of 3 strokes over affected area).
 Willingness to not commence any new medications/
treatments for their neuropathic pain whilst
involved in the trial.
 Women of childbearing potential may participate
providing they are using adequate birth control
methods for the duration of the trial. Included
accepted methods of contraception are, e.g. barrier
methods, intrauterine device (IUD), contraceptive
implant, depot injection, oral contraception and
abstinence (as part of lifestyle choice).
Exclusion criteria
The exclusion criteria are:
 Absolute numbness. This suggests sufficient nerve
damage that will render EN-PENS unlikely to
work [28].
 Known EN-PENS contraindications:
○ Pregnancy; non-pregnancy will be confirmed by
urine test at baseline and at treatment end
(12 weeks)
○ Cardiac pacemakers.
 Other chronic pain or unstable medical conditions
which in the opinion of the investigators would
make the trial unsuitable for the patient.
 Unstable pain intensity or pain medications
6 weeks prior to the study that in the judgment
of the PI would interfere with assessment of
outcome.
 Persons participating in an interventional trial
within the past 3 months.
 Persons participating in a non-interventional trial
completed within the past 2 weeks.
 Diagnosed psychiatric or mental health disorder
which could in the judgment of the PI interfere with
successful study participation. This will be identified
via patient self-report or from case notes.
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trial period of 3 months.
 Inability to complete outcome measures, e.g.
impaired understanding.
 Inability to understand the information necessary to
provide informed consent.
 Other implanted device for the same pain
complaints such as spinal cord stimulator, dorsal
root ganglion stimulator or deep brain stimulator.
 Phantom limb pain as the primary target for
stimulation.
Randomisation
Randomisation will be conducted by an independent
randomisation service via an online system. Randomisa-
tion will use a 1:1 allocation by a computer-generated
randomisation schedule (concealed). Blocking will be
used to ensure a balance between the numbers in the
two groups throughout recruitment. Varying block sizes
will be used. Only site staff authorised to request ran-
domisation will receive passwords for the randomisation
system (PI and Trial Manager (TM)).
Prior to randomisation, pain diaries will be collected
and scored to confirm study inclusion eligibility. Diary
values override values ascertained over the phone, and
patients will be excluded at this point if their diary
values are not in keeping with the inclusion criteria.
Blinding
Study trial nurses, who are blinded as to which is the
active and which is the sham treatment, will be told the
assigned allocation of the patient to either ‘flat electrode’
or ‘pen electrode’ so that they can assign the appropriate
machine to the patient to commence patient training.
Both the research nurses and patients will be able to see
that there are different electrodes, and they will be in-
formed that both interventions deliver electrical current
to the nerve supplying the painful territory and that the
purpose of this trial is to compare two types of electrical
stimulation and find out how much they relieve pain.
Stimulation interventions
In order to maintain blinding, it is important that control
stimulation produces a perceivable but non-therapeutic
electrical stimulation (patient focus group feedback).
Control and active stimulation parameters were developed
in discussion with our collaborator Professor Magerl
(Universität Heidelberg, Center for Biomedicine and
Medical Technology Mannheim, Germany) [13].
Active and control interventions
The active and control machines will look identical. Both
machines will deliver a low-frequency electrical current
of 2 Hz. The machines will differ in terms of connectingelectrode and parameters of amplitude and pulse width.
One machine will use a ball-shaped electrode that will
be placed onto the skin, whilst the other will use a flat
square electrode placed onto the skin. The control
machine will use a different amplitude and pulse width
than the active machine. In the control devices the com-
bination of the electrode shape and the different ampli-
tude and pulse width will prevent electrical stimulation
activating superficial nociceptive A-delta fibres inducing
long-term depression (LTD) of synaptic strength [15, 28].
The display will appear to allow patients the same free-
dom to increase stimulation on both machines to 30 mA;
however, the control devices’ delivered maximal output
will be limited to 6 mA. As the sham control machine will
deliver a small current, these control stimulation parame-
ters were trialled on known EN-PENS responsive patients
to confirm therapeutic non-efficacy.
In order to prevent unblinding, we have not provided
further details, but the authors can be contacted to
request further information.
Stimulation training
Interventions training, visits 2–4
Patients will be taught to use the EN-PENS machine to
which they have been allocated over one to three training
sessions within a 1-week timeframe [19].
Identification of nerve to stimulate In the first training
session, an independent physiotherapist with experience
using EN-PENS will determine the nerve to stimulate
from the patient’s report of pain. This method is in keep-
ing with both the technique used in the previous study
[19] and literature regarding implantable PNS [9, 29]. The
independent physiotherapist will have no further direct
patient contact during the trial. A photograph will be
taken within the first training session of the location of
stimulation and will be used to support the research nurse
and patient in subsequent training sessions and during the
home loan period.
During training, subjects in both groups will be ad-
vised to increase the stimulation amplitude to just above
a perceivable level. Patients will receive no more than
5 minutes of stimulation during training. The LTD effect
would not be obtained within training even if the ac-
tive machine was used, because effective LTD requires
delivery of about 1200 pulses, typically obtained from
10 minutes of treatment [16]. No pain scores will be re-
corded pre- or post-treatment during training sessions.
Treatment phase (home loan), visit 3 or 4
Once the patient is considered to have achieved compe-
tence in using the EN-PENS device, he/she will commence
the 3-month treatment period. Patients will be advised they
need to stimulate for a minimum period of 10 minutes in
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with fixed pulse frequency and pulse width, but will deter-
mine the treatment frequency and stimulation intensity for
themselves. Patients will be advised that the stimulation
amplitude should be mildly painful but not exceed an
unpleasant level. They will also be told that this ‘mildly
painful but not intolerable’ level will differ greatly between
patients, with some patients reaching it at a low milliam-
pere level, others at a higher milliampere level and yet
others not at all. If this mildly painful level is not reached,
maximal stimulation should nevertheless be maintained.
Optional treatment extension/swap, visits 4–5
On completion of the 3-month home loan, participants
will be offered the choice of an optional treatment
extension/treatment swap or termination of the study.
Outcome measures
Primary outcome
The primary outcome is calculation of the average 24-h
pain intensity recorded on an 11-point (0–10) numerical
rating scale (NRS) [30], averaged over the last 7 days of
the 3-month home loan period. The primary outcome
will be assessed with daily completion during the 7-day
screening period (between visit 1 and visit 2) and daily
over the last 7 days of the home loan period.
Pain intensity will also be assessed with weekly comple-
tion of 7-day average pain intensities during the home
loan period and the optional extension. This will be
measured using pain diaries that also record treatment
frequency in order to monitor study adherence.
Additionally any symptoms and adverse events (any
undesirable symptom or experience associated with
treatment) will be recorded.
Secondary outcomes
The secondary outcomes are:
 Brief Pain Inventory Interference Subscale
(functional interference) score [31]
 Health-related quality of life questionnaire
(EuroQol-5D-5 L) score [32]
 Completion of a modified Client Service Receipt
Inventory (CSRI) (health care resource use) [33],
supported by a regular telephone questionnaire [34].
Functional interference and health care resource use
will be recorded at baseline and at 3 months. EuroQOL-
5D-5 L score will be recorded at baseline and at 1, 2 and
3 months.
Exploratory outcomes
Exploratory outcomes are: Hospital Anxiety and Depression Scale [35]
(emotional function) score
 Pain Self-Efficacy Questionnaire [36] (perceived
confidence to function despite pain) score
 Allodynia mapping (change in surface area of
allodynia [37])
 Neuropathic Pain Symptom Inventory (NPSI) [38]
(quality of pain) score
 A one-off specially designed sensory testing protocol
(assessment of potential working mechanisms of
EN-PENS), to be performed for approximately 40
patients who consent to testing
 Changes in medication consumption as they occur
 A case review by a named pain consultant
specialising in spinal cord stimulation (potential
medical suitability for invasive neuromodulation).
Exploratory measures will be recorded at baseline and
at 3 months unless otherwise stated.
Outcomes noted on completion of the study only are:
 Patient-perceived global impression of change [39]
 Success of blinding [40].Definition of end of study
The end of the study will be the last participant’s final
study contact at day 196 (+/–14 days, for those who
participate in the open extension/treatment swap) or at
day 112 (+/– 14 days, for those who elect not to enter
the open extension/swap).Sample size
Within the previous study we observed a post-treatment
NRS reduction of 6.4 to 3.6 (average difference 2.8) for
the entire group (n = 20), and 6.6 to 3.1 (average differ-
ence 3.5) within the peripheral neuropathic pain group
(n = 8) [19]. The mean observed effect for the treatment
group would remain 3.5 only if the control group
showed no change over time. There was no control
group as part of this study; therefore, we estimated
potential control group response based on best available
literature. We were unable to identify any systematic
reviews indicating baseline pain intensities and placebo
responses specifically in RCTs for post-injury neuropathic
pain. Therefore, data from a systematic review and meta-
analysis on a different post-traumatic neuropathic pain
condition, complex regional pain syndrome, was used
[41]. In this systematic review the pooled mean at baseline
for pain (17 studies assessed in the non-active arms) was
6.4. The systematic review illustrated no significant
evidence of placebo response at time points comparable
to our proposed trial. Given the observed effect size from
our published audit, the proposed group difference of 1.5
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between-group effect size differences.
It is conservatively estimated that there is a correlation
of 0.5 between the baseline and outcome pain scores; in
our audit the correlation was 0.64. With a 5% significance
level and 90% power, 26 participants per group are
required. Allowing for a 30% dropout, based on results
from a prospective patient audit, a sample size of 38
participants per group is required, 76 in total.Data handling
Stored data will be coded and anonymised information
and will be stored securely: all electronic data will be
password protected. Hard copy data will be stored in a
locked filing cabinet in a secure office for 5 years.Statistical analysis
Data analysis will be according to the intention-to-treat
principle. The primary analysis will be of observed data
only, with missing values omitted from the analysis.
Therefore, patients who do not contribute any outcome
data will not be analysed. The primary outcome will be
analysed using analysis of covariance (ANCOVA). Baseline
pain scores will be considered as a covariate in the
analysis. The mean difference in outcome between the
two groups will be reported with 95% confidence intervals.
As a secondary analysis of the primary outcome, the pain
scores will also be considered an ordinal outcome (as
opposed to continuous for the primary analysis).
A sensitivity analysis will be performed using multiple
imputation to address missing values. The extent of
missing values will be investigated, as will the nature of
variables with missing data. For the sensitivity analysis,
multiple imputation will be performed based on either
the multivariate normal data distribution [42] or using
chained equations [43]. Ordinal logistic regression will
be used to compare between groups as an additional
sensitivity analysis [44].
Secondary and exploratory continuous outcomes will
be analysed using ANCOVA as with the primary outcome
[45]. For binary outcomes the number and percentage of
patients experiencing the event for each treatment arm
will be presented. The relative risk and 95% confidence
interval will be presented, and the chi-squared test will be
used to determine statistical significance [46]. Adverse
events will be analysed using descriptive statistics only, as
there is unlikely to be sufficient power to formally com-
pare occurrence.
The occurrence and reasons for missing data will be
examined via multiple imputation methods to analyse
factors such as self-efficacy in relation to adherence.
Additionally, a post hoc analysis will be used to assess
whether there is a correlation between efficacy andsymptom profiling using the specified Neuropathic Pain
Symptom Inventory.
Health economic analysis
There are no economic analyses of EN-PENS relevant to
a UK context. A de novo prospective economic evalu-
ation is therefore warranted, given the cost differential
between the interventions being evaluated and the
potential for clinical benefits (should the null hypothesis
be disproved). The health economic analysis will adopt
the perspective of the National Health Service (NHS)
and Personal Social Services. Costs will include those of
treatment, procedures and investigations, contact with
primary and secondary care services and personal social
services. Resource use will be obtained from patients’
self-reporting of resource use, captured by telephone
questionnaire administration [47] and retrospective case
report form. Unit cost data will be obtained from standard
sources [33, 48, 49]. The primary economic outcomes will
be the incremental cost per quality-adjusted life year
(QALY) gained, estimated by administering the EQ-5D-
5 L. The number of QALYs experienced by each patient
will be calculated as the area under the curve, using the
trapezoidal rule, applying the UK tariffs. Total costs will
be combined with QALYs to calculate the incremental
cost-utility ratio, which will be compared with the £20,000
to £30,000 per QALY threshold of cost-effectiveness. A
range of one-way sensitivity analyses will be conducted to
assess the robustness of the analysis, and multivariate sen-
sitivity analyses will be applied where interaction effects
are suspected. The joint uncertainty in costs and benefits
will be considered through the application of bootstrap-
ping and the estimation of cost-effectiveness acceptability
curves [50].
Withdrawal of participants
The study treatment must be discontinued and patients
withdrawn if:
 Participants decide they no longer wish to continue
(see also below)
 Recommended by the Investigator or another
clinician (e.g. due to intercurrent illness during
course of study or increased pain following repeated
stimulation)
 The trial is terminated if deemed appropriate by the
study staff in consultation with the study’s PI and
pain consultant.
Where appropriate, patients who wish to discontinue
their study intervention or for whom discontinuation is
advised will be asked whether they would be willing to
continue in the study by providing weekly diaries.
Patients are also withdrawn if:
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treatment (i.e. the first training session is never
started — this is also termed ‘non-compliance’)
 They fail to complete weekly pain diary reports on
three consecutive occasions or 4 nonconsecutive
weeks that include the last month of treatment
(this is also termed ‘missing data’).
All data from patients randomised to treatment will be
included in the intention-to-treat analysis (see ‘Statistical
analysis’).
Participants have the right to withdraw from the study
at any time without providing a reason. The Investigator
also has the right to withdraw a participant from the
study if they consider that it is in the best interests of
the participant (adverse events). Should a participant
decide to withdraw from the study, he/she will be asked
to volunteer a reason for withdrawal.
Subjects who withdraw from treatment early will be
encouraged to return to the study site to have follow-up
outcomes (week 13), providing that consent is not with-
drawn. Participants who withdraw early will be expected
to return all study equipment within 2 weeks of ending
the study.Trial organisation and monitoring
The EN-PENS protocol has been extensively reviewed
by clinicians, statisticians and patient groups. The trial
has been registered with an International Standard
Randomised Controlled Trial Number (ISRCTN), regis-
tration number ISRCTN53432663. All aspects of trial
administration will be conducted by the Sponsor site
Neurosciences Research Unit and finance departments.
An external project monitor will also be appointed as
part of data quality assurance. The Neurosciences Re-
search Unit trials manager will supervise Neurosciences
Research Unit staff.
Day-to-day trial management by the TM and PI will
include establishing and carrying out the trial in accord-
ance with international, national and local laws and
regulations and good clinical practice (GCP). PI mentor-
ship and support will be provided by pain consultants
AG and TJ Nurmikko.
Quarterly trial management meetings will review the
day-to-day running and management of the trial. Members
will include the PI, TM, Data Manager, health economists
(DH and EH), trial statistician, pain consultant AG, and
consumer representative Wendy Hall.
The trial management group will report to a trial
steering group who will provide overall supervision of
the trial and ensure milestones are met and the trial
adheres to Medical Research Council (MRC) Guidelines
for Good Clinical Practice in Clinical Trials.The trial steering group will comprise the PI, the TM
and five to six persons independent of the trial running.
It will also include a consumer representative.
Annual reports will be presented by the PI to the
centres, research governance committee and pain
services management group and National Institute for
Health Research (NIHR) funders.
The study may also be subject to audit or inspection
by the University of Liverpool or the Walton NHS Trust
under their remit as Co-sponsors, or by the Medical
Health Research Authority (MHRA) or other regulatory
bodies to ensure adherence to GCP and regulatory
requirements.
Direct access to source data and documents
The investigators agree to provide full access to all source
data, study data and materials to the trust research
governance department, ethics committee, regulatory
authority and Trial Manager for purposes of monitoring,
audit or inspection.
Expected adverse reactions
Skin irritation may be expected in persons who demon-
strate sensitivity to aqueous gel or electrode pads. These
adverse events are expected in the sense that they are
possible known side effects of the study intervention. All
reported instances of both serious and non-serious
adverse events will be reported in this study.
Recording and reporting non-serious adverse events and
serious adverse events/reactions (including suspected
unexpected serious adverse reactions)
All adverse events and all serious adverse events (SAEs)
should be recorded. All non-serious adverse events will
be recorded on the study case report forms. Relation of
any adverse events to treatment should be assessed by
the trials pain consultant. All SAEs, serious adverse reac-
tions (SARs) and suspected unexpected serious adverse
reactions (SUSARs) shall be recorded and reported on
the SAE form to the trial medic and PI within 24 hours
of learning of its occurrence.
Relationship to the treatment will be assessed by the
trials pain consultant. As this is a blinded trial involving
a control and active treatment, seriousness, causality and
expectedness should be evaluated as though the patient
were on the active treatment. The Sponsor will report
SUSARs and other SARs to the regulatory authority
(MHRA) in accordance with the reporting timelines.
The PI will report to the North West Coast - Preston
ethics committee.
The PI is unblinded throughout the study; therefore,
reporting of incidents will not affect the integrity of the
trial blinding.
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Results from the study will be submitted for publication
by the investigators only, in international medical journals.
Results of the study will also be reported to the Sponsor
and Funder in the required format.
Participants will be provided with a summary of the
results once the primary paper has been accepted for
publication.
Discussion
This protocol will allow us to determine if external non-
invasive peripheral nerve stimulation is an effective
treatment for neuropathic pain following peripheral
nerve injury. The aim is to have 76 patients recruited by
30 August 2018 with the write-up completed by 30
August 2019.
Trial status
The current status is open, the closure date is 30 August
2018 and the global sample size is 76.
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